VRCA

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing and selling medications for skin diseases requiring medical intervention. The Company's product portfolio consists of one approved product with several potential follow-on indications, as well as an additional pipeline product. Its commercial product, YCANTH (VP-102), is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. YCANTH (VP-102) is being developed for the treatment of molluscum contagiosum in adult and pediatric patients two years of age and older. It is also engaged in developing YCANTH (VP-102) for a potential follow-on indication for the treatment of common warts. Its second development candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma (BCC).

Wall Street analysts forecast VRCA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VRCA is 19.00 USD with a low forecast of 19.00 USD and a high forecast of 19.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Verrica Pharmaceuticals Inc revenue for the last quarter amounts to 14.34M USD, decreased -905.39 % YoY.

Verrica Pharmaceuticals Inc. EPS for the last quarter amounts to -0.03 USD, decreased -99.39 % YoY.

Verrica Pharmaceuticals Inc (VRCA) has 71 emplpoyees as of December 15 2025.

Today VRCA has the market capitalization of 75.16M USD.